AXERT: payments to doctors
Payments that named AXERT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $19K
- Providers
- 347
- Transactions
- 646
- Average per transaction
- $29
The per-transaction average — $29 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 347 providers the average total is $54, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $8,907 | 47.5% |
| Johnson & Johnson Vision Care, Inc. | $6,657 | 35.5% |
| Johnson & Johnson Surgical Vision, Inc. | $1,681 | 9.0% |
| Medical Device Business Services, Inc. | $678 | 3.6% |
| Biosense Webster, Inc. | $321 | 1.7% |
| Janssen Scientific Affairs, LLC | $252 | 1.3% |
| Mentor Worldwide LLC | $120 | 0.6% |
| Janssen Research & Development, LLC | $76 | 0.4% |
| Ethicon Endo-surgery Inc. | $75 | 0.4% |